Tags

Type your tag names separated by a space and hit enter

S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis.
Respir Med. 2012 Apr; 106(4):571-80.RM

Abstract

BACKGROUND

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, and the prognosis remains poor. On the other hand, other fibrotic interstitial pneumonias such as idiopathic nonspecific interstitial pneumonia (I-NSIP) and collagen vascular disease-associated interstitial pneumonia (CVD-IP) resemble IPF, but they respond to therapy and the prognosis is better. We searched for biomarkers to distinguish IPF from other fibrotic interstitial pneumonias and investigated whether S100A9 could be useful for discriminating types of fibrotic interstitial pneumonia based on our preliminary proteomic findings.

METHODS

We measured S100A9 levels in serum and bronchoalveolar lavage fluid (BALF) from 28 patients with IPF, 15 with I-NSIP, 20 with cryptogenic organizing pneumonia (COP), 35 with CVD-IP and 23 healthy individuals (controls) using enzyme-linked immunosorbent assays. S100A9 in the lung was also immunohistochemically localized.

RESULTS

S100A9 levels in BALF, but not in serum, were significantly elevated in patients with IPF compared with I-NSIP, COP, CVD-IP and healthy individuals. S100A9 immunoreactivity was localized mainly in macrophages and neutrophils in lung specimens from patients with IPF. The results of receiver operating characteristic (ROC) curve analysis showed that BALF S100A9 levels had sufficient specificity and sensitivity to distinguish IPF from I-NSIP and CVD-IP.

CONCLUSION

S100A9 in BALF might serve as a candidate biomarker to discriminate between IPF and other fibrotic interstitial pneumonias.

Authors+Show Affiliations

Second Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22209187

Citation

Hara, Atsuko, et al. "S100A9 in BALF Is a Candidate Biomarker of Idiopathic Pulmonary Fibrosis." Respiratory Medicine, vol. 106, no. 4, 2012, pp. 571-80.
Hara A, Sakamoto N, Ishimatsu Y, et al. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respir Med. 2012;106(4):571-80.
Hara, A., Sakamoto, N., Ishimatsu, Y., Kakugawa, T., Nakashima, S., Hara, S., Adachi, M., Fujita, H., Mukae, H., & Kohno, S. (2012). S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respiratory Medicine, 106(4), 571-80. https://doi.org/10.1016/j.rmed.2011.12.010
Hara A, et al. S100A9 in BALF Is a Candidate Biomarker of Idiopathic Pulmonary Fibrosis. Respir Med. 2012;106(4):571-80. PubMed PMID: 22209187.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. AU - Hara,Atsuko, AU - Sakamoto,Noriho, AU - Ishimatsu,Yuji, AU - Kakugawa,Tomoyuki, AU - Nakashima,Shota, AU - Hara,Shintaro, AU - Adachi,Misato, AU - Fujita,Hanako, AU - Mukae,Hiroshi, AU - Kohno,Shigeru, Y1 - 2011/12/30/ PY - 2011/10/04/received PY - 2011/12/12/revised PY - 2011/12/13/accepted PY - 2012/1/3/entrez PY - 2012/1/3/pubmed PY - 2012/5/11/medline SP - 571 EP - 80 JF - Respiratory medicine JO - Respir Med VL - 106 IS - 4 N2 - BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, and the prognosis remains poor. On the other hand, other fibrotic interstitial pneumonias such as idiopathic nonspecific interstitial pneumonia (I-NSIP) and collagen vascular disease-associated interstitial pneumonia (CVD-IP) resemble IPF, but they respond to therapy and the prognosis is better. We searched for biomarkers to distinguish IPF from other fibrotic interstitial pneumonias and investigated whether S100A9 could be useful for discriminating types of fibrotic interstitial pneumonia based on our preliminary proteomic findings. METHODS: We measured S100A9 levels in serum and bronchoalveolar lavage fluid (BALF) from 28 patients with IPF, 15 with I-NSIP, 20 with cryptogenic organizing pneumonia (COP), 35 with CVD-IP and 23 healthy individuals (controls) using enzyme-linked immunosorbent assays. S100A9 in the lung was also immunohistochemically localized. RESULTS: S100A9 levels in BALF, but not in serum, were significantly elevated in patients with IPF compared with I-NSIP, COP, CVD-IP and healthy individuals. S100A9 immunoreactivity was localized mainly in macrophages and neutrophils in lung specimens from patients with IPF. The results of receiver operating characteristic (ROC) curve analysis showed that BALF S100A9 levels had sufficient specificity and sensitivity to distinguish IPF from I-NSIP and CVD-IP. CONCLUSION: S100A9 in BALF might serve as a candidate biomarker to discriminate between IPF and other fibrotic interstitial pneumonias. SN - 1532-3064 UR - https://www.unboundmedicine.com/medline/citation/22209187/S100A9_in_BALF_is_a_candidate_biomarker_of_idiopathic_pulmonary_fibrosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(11)00476-8 DB - PRIME DP - Unbound Medicine ER -